Terns Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 15.82 million compared to USD 14.25 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.56 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.835 USD | -1.60% | -4.40% | -9.55% |
13/05 | Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
08/05 | Terns Pharmaceuticals, Inc. Announces Executive Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.55% | 384M | |
+59.79% | 62.59B | |
-2.30% | 41.18B | |
+44.36% | 40.29B | |
-8.29% | 27.9B | |
+12.84% | 26.21B | |
-21.64% | 19.09B | |
+6.00% | 13.08B | |
+24.33% | 12.26B | |
+27.24% | 12.05B |
- Stock Market
- Equities
- TERN Stock
- News Terns Pharmaceuticals, Inc.
- Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022